Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).

MLA

Hochster, Howard S., et al. “Combining Antivascular Endothelial Growth Factor and Anti-Epidermal Growth Factor Receptor Antibodies: Randomized Phase II Study of Irinotecan and Cetuximab with/without Ramucirumab in Second-Line Colorectal Cancer (ECOG-ACRIN E7208).” JNCI: Journal of the National Cancer Institute, vol. 116, no. 9, Sept. 2024, pp. 1487–94. EBSCOhost, https://doi.org/10.1093/jnci/djae114.

APA

Hochster, H. S., Catalano, P., Weitz, M., Mitchell, E. P., Cohen, D., O’Dwyer, P. J., Faller, B. A., Kortmansky, J. S., O’Hara, M. H., Kricher, S. M., Lacy, J., Lenz, H.-J., Verma, U., & Benson, A. B. (2024). Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). JNCI: Journal of the National Cancer Institute, 116(9), 1487–1494. https://doi.org/10.1093/jnci/djae114

Chicago

Hochster, Howard S, Paul Catalano, Michelle Weitz, Edith P Mitchell, Deirdre Cohen, Peter J O’Dwyer, Bryan A Faller, et al. 2024. “Combining Antivascular Endothelial Growth Factor and Anti-Epidermal Growth Factor Receptor Antibodies: Randomized Phase II Study of Irinotecan and Cetuximab with/without Ramucirumab in Second-Line Colorectal Cancer (ECOG-ACRIN E7208).” JNCI: Journal of the National Cancer Institute 116 (9): 1487–94. doi:10.1093/jnci/djae114.